The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

DelveInsight's Alzheimer's Disease Pipeline report depicts a robust space with 200+ active players working to develop 220+ ...

Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...